SynBiotic SE

XETRA SBX.DE

SynBiotic SE EBT Margin for the year ending December 31, 2023: -307.44%

SynBiotic SE EBT Margin is -307.44% for the year ending December 31, 2023, a 4.13% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.
  • SynBiotic SE EBT Margin for the year ending December 31, 2022 was -320.69%, a -117.57% change year over year.
  • SynBiotic SE EBT Margin for the year ending December 31, 2021 was -147.39%, a -839.18% change year over year.
  • SynBiotic SE EBT Margin for the year ending December 31, 2020 was -15.69%.
Key data
Date EBT Margin Net Income Margin EBITDA Margin EBIT Margin
Market news
SV Wall Street
XETRA: SBX.DE

SynBiotic SE

CEO Mr. Daniel Kruse
IPO Date Jan. 7, 2021
Location Germany
Headquarters Innere Wiener Str. 14
Employees 55
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Personal Care Pet Food Snack Foods Tobacco
Description

SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.

StockViz Staff

February 5, 2025

Any question? Send us an email